FXN and Friedreich ataxia: Overall, this study strengthens the role of NRF2 as a central therapeutic target in FRDA and contributes to position FRDA in the “NRF2 diseasome”, a new approach assembling disease phenotypes joined by NRF2 defects [2,3].